Ken Griffin Matinas Bio Pharma Holdings, Inc. Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.46 - $42.69 $14,400 - $1.34 Million	31,305 Added 150.5%	52,106 $26,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $33.0 $13,104 - $686,433	20,801 New	20,801 $13,000
Q1 2022 May 16, 2022	SELL	$0.5 - $1.06 $59,019 - $125,121	-118,039 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.92 - $1.22 $61,479 - $81,527	-66,826 Reduced 36.15%	118,039 $119,000
Q3 2021 Nov 15, 2021	SELL	$0.67 - $1.51 $86,999 - $196,073	-129,850 Reduced 41.26%	184,865 $241,000
Q1 2021 May 17, 2021	BUY	$0.96 - $1.74 $199,442 - $361,490	207,753 Added 194.23%	314,715 $330,000
Q4 2020 Feb 16, 2021	BUY	$0.76 - $1.47 $25,477 - $49,278	33,523 Added 45.65%	106,962 $145,000
Q3 2020 Nov 16, 2020	SELL	$0.67 - $0.96 $29,079 - $41,665	-43,402 Reduced 37.15%	73,439 $56,000
Q2 2020 Aug 14, 2020	BUY	$0.52 - $0.92 $60,757 - $107,493	116,841 New	116,841 $90,000
Q1 2020 May 15, 2020	SELL	$0.6 - $2.31 $16,668 - $64,171	-27,780 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.63 - $2.27 $47,764 - $172,104	-75,817 Reduced 73.18%	27,780 $63,000
Q4 2018 Feb 14, 2019	BUY	$0.53 - $1.11 $48,939 - $102,495	92,338 Added 820.13%	103,597 $62,000
Q2 2018 Aug 10, 2018	SELL	$0.42 - $0.74 $5,604 - $9,875	-13,345 Reduced 54.24%	11,259 $0
Q1 2018 May 11, 2018	SELL	$0.76 - $1.32 $15,300 - $26,574	-20,132 Reduced 45.0%	24,604 $19,000
Q4 2017 Feb 09, 2018	BUY	$1.1 - $1.54 $49,209 - $68,893	44,736	44,736 $52,000

3.52M

Ticker MTNB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,864,992
Market Cap $134M
Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.